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Objectives – To characterize the response of horse skin following intradermal injection of 
polyclonal rabbit anti-canine IgE (anti-IgE) and rabbit immunoglobulin G (IgG) in an attempt to 
develop a model of equine allergic skin disease. 
Study design - In vivo study.  
Animals – 10 Adult Thoroughbred horses. 
Methods –Horses were injected intradermally with one of two different concentrations of anti-
IgE and rabbit immunoglobulin G (IgG). Wheal measurements and injection site biopsies were 
obtained before and 20 min, 6 hr, 24 hr, and 48 hr after injection. Tissue sections were stained 
with Hematoxylin and Eosin, Luna, and Toluidine Blue. Immunohistochemistry for CD3+, 
CD4+, and CD8+ cells was performed. Cells were counted in 1 mm2 of dermis and divided over 
four depths for standard stains: superficial dermal, superficial follicular, deep follicular, and deep 
follicular to adnexal. The superficial dermis was evaluated in immunohistochemistry sections.  
Results – Lower concentrations of anti-IgE produced suboptimal responses, so the higher 
concentration injections were evaluated. Anti-IgE wheals were significantly larger than IgG 
wheals at 20 min, 6 hr, and 24 hr after injection. Anti-IgE injected skin had significantly more 
degranulated mast cells than IgG injected skin and there were significantly more inflammatory 
cells (6 hr, 24 hr), eosinophils (6hr, 24hr, 48hr), and neutrophils (6 hr). Eosinophil counts 
significantly increased in anti-IgE samples in the deeper but not superficial dermis when 
compared to IgG samples. There were more eosinophils in the deeper dermis of anti-IgE injected 
skin. There were no significant differences between anti-IgE and IgG injected skin for CD3+, 
CD4+, or CD8+ cells. 
Conclusion - Injection of anti-IgE antibodies at a higher concentration was associated with the 





degranulation and accumulation of inflammatory cells, particularly eosinophils and neutrophils.  
This pattern was similar to that seen in horses with spontaneous allergic skin disease, although 
lymphocytes were not increased. 
Clinical Relevance - This study documents the response to intradermal anti-IgE injection in 





CHAPTER 1   GENERAL INTRODUCTION 
1.1   Type I Hypersensitivity Reactions 
Hypersensitivity reactions are allergic reactions that are provoked by exposure (and subsequent 
re-exposure) to an antigen (allergen) and can involve skin, eyes, the respiratory system, and the 
gastrointestinal tract. The most common allergens include proteins in pollen, house dust mites, animal 
dander, and other chemicals (Abbas et al., 2012). Upon initial exposure to an allergen, naïve T cells 
differentiate into TH2 T cells. TH2 cells interface with naïve B cells via CD40-CD40 ligand interactions.  
They also secrete TH2 cytokines such as IL-4 and IL-13. Together, these signals induce B cells to 
produce antibodies and promote the switch of antibody forms (isotypes) from IgM to other classes, 
especially IgE.  In some species, certain isotypes of IgG (such as IgGT in the horse (Wagner et al., 
2006)) may also mediate hypersensitivity reactions, but the relevance of these isotypes to clinical 
disease is unclear. 
Perhaps the most common clinical forms of hypersensitivity involve Type I (immediate, IgE 
mediated) hypersensitivity reactions.  These reactions may manifest in a biphasic fashion, consisting of 
immediate and late-phase reactions (not to be confused with Type IV delayed hypersensitivity 
reactions). The immediate reaction begins upon re-exposure to an antigen to which an individual has 
already become sensitized.  Allergen-specific IgE is bound to high-affinity receptors (FcεRI) on the 
surface of mast cells.  These receptors may also be found on other cells, such as basophils, eosinophils, 
epidermal Langerhans cells, dermal macrophages and activated monocytes (Abbas et al., 2012). 
Exposure to allergen results in allergen binding to this surface bound IgE and “cross-linking” these 
receptors.  This cross-linking activates the mast cells and causes them to release a variety of mediators. 
One subset of mast cell mediators includes the biogenic amines (ie. histamine, serotonin) that cause the 
immediate reaction by inducing vasodilation and vascular leakage. Histamine causes vasodilation by 





endothelial cell contraction, leading to increased vascular permeability (Abbas et al., 2012). It is these 
effects of histamine that are responsible for `the typical wheal-and-flare response that is associated with 
immediate hypersensitivity reactions. Mast cells also release granule enzymes and proteoglycans that 
contribute to tissue damage in the immediate phase (Abbas et al., 2012). Mast cell activation also leads 
to the synthesis and release of lipid-derived mediators, the most important of which are derived from 
arachidonic acid. Prostaglandin D2 binds to smooth muscle cell receptors and acts as a vasodilator, a 
bronchoconstrictor, and promotes neutrophil chemotaxis to sites of inflammation (Abbas et al., 2012). 
Leukotrienes are also produced, which promote bronchoconstriction and possibly contribute to the 
wheal-and-flare reaction. Platelet activating factor, also mast-cell derived, can promote 
bronchoconstriction, vascular smooth muscle relaxation, and endothelial cell retraction (Abbas et al., 
2012). In addition to aiding B class switching, TH2 cells are involved in immediate hypersensitivity in 
other ways. TH2 secreted IL-5 activates eosinophils and increases their maturation while IL-13 
stimulates increased secretion of mucus by epithelial cells (such as those in the airways) (Abbas et al., 
2012). 
The second aspect of Type I hypersensitivity reactions is the late phase reaction.  Late-phase 
reactions are mediated by cytokines from TH2 cells and mast cells, as well as lipid mediators from mast 
cells. The late-phase reaction is characterized by increased numbers of neutrophils, eosinophils, 
macrophages, and CD4+ cells. Mast cell derived cytokines include tumor necrosis factor, which activates 
endothelial cell expression of adhesion molecules and contributes to neutrophil and monocyte 
infiltration. Mast cells and TH2 cells produce IL-4, which enhances the endothelial expression of 
adhesion molecules for eosinophils, such as E-selectin and VCAM-1. This contributes directly to the 
accumulation of eosinophils and other inflammatory cells at the site of the reaction. Epithelial cells at 
allergic reaction sites produce CCL11 (eosinophil chemotactic protein), which binds to CCR3 on 





surface-bound IgE. They then secrete granule proteins (such as platelet activating factor, prostaglandins 
and leukotrienes) that further contribute to allergic disease by inducing tissue damage and continuing 
inflammatory cell recruitment. Neutrophils and other cells can also be recruited to the site of 
inflammation in late-phase reactions.  
1.2  Anti Immunoglobulin-E 
Anti-IgE is an antibody that is generated in one species (rabbits in Chapters 2 and 3) that is 
capable of binding and cross-linking mast cell bound IgE molecules in another species (dogs in Chapter 
2 and 3). This binding and cross-linking produces activation of mast cells in a manner similar to that 
seen with naturally occurring Type I hypersensitivity reactions and has been used as a model for 
spontaneous disease. The benefit of using anti-IgE rather than allergen to produce mast cell 
degranulation is that (instead of requiring a population of specifically-sensitized individuals), the anti-
IgE antibodies can bind any IgE and induce cross-linking and activation. Using anti-IgE also means that 
a large amount of IgE specific for any particular antigen isn’t needed. Additionally, even normal, non-
allergic individuals have some IgE bound to their mast cells, making them acceptable subjects for 
studies using anti-IgE. 
Intradermal injection of anti-canine IgE antibodies has been demonstrated in dogs to produce 
immediate and late-phase reactions in the skin that mimic those of spontaneously occurring allergy 
(Olivry et al., 2001; Pucheu-Haston et al., 2006). Urticarial reactions were seen in atopic and normal 
dogs 20 minutes following injection of anti-canine IgE (Olivry et al., 2001). There continued to be 
grossly visible lesions characterized by erythema and dermal thickening in the same subset of dogs up to 
24 hours later. These gross lesions were similar to those seen in mite- allergic atopic dogs following 
exposure to Dermatophagoides farinae (Olivry et al., 2001). Late-phase reactions in normal and atopic 





eosinophils and later recruitment αβ T-lymphocytes and dermal dendritic cells. This appearance was 
generally similar to the reaction seen in atopic dogs exposed to Dermatophagoides farinae in the same 
study (Olivry et al., 2001). These results of normal dogs exposed to anti-IgE were later confirmed in 
another study (Pucheu-Haston et al., 2006).  
One use for this model is in the pre-clinical evaluation of treatments for allergic disease.  In 
dogs, studies have characterized the anti-inflammatory effects of drugs such as prednisolone (Pucheu-
Haston et al., 2006), hydrocortisone (Rivierre et al., 2000), and triamcinolone (DeBoer, 2000). Similar 
studies have been performed in humans for different potential allergy treatments (Gronneberg and Raud, 
1996; Gronneberg and Strandberg, 1985; Gronneberg et al., 1981; Gronneberg and Zetterstrom, 1985b, 
1990b). 
1.3  IgE-Mediated Allergic Skin Disease in Horses 
Allergic skin disease in horses includes, but is not limited to, insect bite hypersensitivity and 
atopic dermatitis. Insect bite hypersensitivity (IBH) (a.k.a. sweet itch, summer eczema) is the most 
common allergy in horses, and has subsequently become the most studied. The causative insects are 
frequently Culicoides spp. midges, and the allergens responsible are likely salivary in origin (Hellberg et 
al., 2006; Langner et al., 2009; Schaffartzik et al., 2011; Wilson et al., 2008). The prevalence of IBH 
varies based on breed and geographic location, but has been reported to be up to 71.4% (Bjornsdottir et 
al., 2006; Braverman et al., 1983; Halldordsottir and Larsen, 1991; Littlewood, 1998; van Grevenhof et 
al., 2007). The disease severity is variable and clinical signs include pruritus, papules, hyperesthesia, 
urticaria, edema, and secondary self-trauma (Brostrom et al., 1987; Scott, 2010). Lesion location varies 
based on the type of insect involved. Research has demonstrated that the disease is IgE-mediated (van 
der Haegen et al., 2001; Wagner et al., 2006; Wilson et al., 2001). There is also evidence supporting a 





Less information is available about non-IBH related atopic dermatitis in horses.  Clinical signs 
include pruritus, recurrent urticaria, and lesions secondary to itch (Fadok, 2013; Scott, 2010). Reports of 
prevalence and breed predisposition are anecdotal and are generally not confirmed by population-
controlled analyses. Much of the information that is assumed about atopic dermatitis in horses is 
extrapolated from humans and dogs (Fadok, 2013). There are some retrospective studies available 
detailing the success (or lack thereof) of treatments for atopic dermatitis in horses, but the information is 
lacking when compared what is known about treatment options and efficacy in humans and dogs (Olsen 
et al., 2011; Rees, 2001; Stepnik et al., 2012). Effective pre-clinical evaluation of the efficacy of novel 
anti-allergic therapies requires the ability to consistently produce or reproduce allergic inflammation.  
For this reason, there is a great need for the development of a practical model that induces responses 
similar to those seen in atopic horses.  
While a large amount of information is available about IBH, including prevalence and 
histopathology findings, there is little peer-reviewed information regarding various treatments and long-
term outcomes (O'Neill et al., 2002; Olsen et al., 2011; van den Boom et al., 2010).  There is even less 
information regarding treatment and prognosis associated with non-IBH related atopic dermatitis.  
Research in the field of allergic skin disease in horses has been hampered, at least in part, by the need 
for a practical model of the disease.  In the ideal situation, horses with spontaneous allergic skin disease 
would be studied.  However, development and long-term maintenance of a dedicated herd of sensitized 
horses with allergic skin disease is difficult and expensive.  In addition, generation of allergen-specific 
responses in these sensitized horses typically requires the administration of commercial allergen 
extracts.  Many of these extracts may contain proteolytic compounds and/or induce nonspecific 
inflammatory responses even in non-sensitized horses (Lorch et al., 2001b).  Thus, it would be desirable 





spontaneous disease using non-allergic horses, without the additional variables associated with allergen 




















CHAPTER 2   CHARACTERIZATION OF IgE-MEDIATED (LOWER 
CONCENTRATION) CUTANEOUS IMMEDIATE AND LATE-PHASE REACTIONS 
IN NON-ALLERGIC HORSES 
2.1  Introduction 
Hypersensitivity disorders in the horse are frequently associated with the development of skin 
disease. These allergic diseases, such as insect bite hypersensitivity, atopic dermatitis, and urticaria, 
cause variable signs in horses, including pruritus, pain, and changes to coat and hair (Scott, 2010). In 
severe cases, horses can lose body condition and exhibit significant decreases in athletic performance.   
The true prevalence of most equine allergic skin diseases is unknown with the exception of insect bite 
hypersensitivity, for which the prevalence has been reported to vary from 11.6 to 71.4% (Bjornsdottir et 
al., 2006; Braverman et al., 1983; Halldordsottir and Larsen, 1991; Littlewood, 1998; van Grevenhof et 
al., 2007). Research in the field of allergic skin disease in horses has been hampered, at least in part, by 
the need for a practical model of the disease.  In the ideal situation, horses with spontaneous allergic skin 
disease would be studied.  However, development and long-term maintenance of a dedicated herd of 
sensitized horses with allergic skin disease is difficult and expensive.  In addition, generation of 
allergen-specific responses in these sensitized horses typically requires the administration of commercial 
allergen extracts.  Many of these extracts may contain proteolytic compounds and/or induce nonspecific 
inflammatory responses even in non-sensitized horses (Lorch et al., 2001b).  Thus, it would be desirable 
to develop a model that can consistently and easily mimic many or all of the changes associated with 
spontaneous disease using non-allergic horses, without the additional variables associated with allergen 
extract administration.  Similar approaches have been used to effectively model cutaneous allergic 
inflammation in other species, including dogs (Olivry et al., 2001; Pucheu-Haston et al., 2006) and 
humans (Gronneberg, 1984; Gronneberg and Strandberg, 1985; Gronneberg et al., 1981; Gronneberg 





Briefly, allergic skin disease is often mediated by Type I hypersensitivity reactions. These 
reactions (immediate- and late-phase hypersensitivity) are initiated by antigen exposure. Upon exposure, 
naïve antigen-specific T cells are induced to differentiate into TH2 phenotype cells which then activate B 
cells. The B cells undergo class switching and begin to produce IgE, which binds to the high affinity 
receptor for IgE (FcεRI) on the surface of mast cells. Upon future exposure to the same antigen, the 
surface-bound IgE is cross-linked and the mast cells become activated. The mast cells release mediators 
(histamine, cytokines, leukotrienes) that lead to the development of immediate- and late-phase 
hypersensitivity reactions. Late-phase reactions are characterized by an influx of inflammatory cells, 
including neutrophils, eosinophils, basophils and T-cells six to 48 hours after challenge (Charlesworth, 
1994; Frew and Kay, 1988; Olivry et al., 2001). 
Atopic dermatitis (Scott, 2010) and insect bite hypersensitivity (Petersen, 2009; Scott, 2010) in 
horses involve type I hypersensitivity reactions. The involvement of IgE, specifically, has been 
suggested (Lorch et al., 2001b; van der Haegen et al., 2001) and established (Rufenacht et al., 2005; 
Wagner et al., 2006) in equine allergic skin disease. Horses affected by insect bite hypersensitivity have 
been shown to have increased expression of both IgE protein and mRNA in dermal cells in affected skin 
when compared to unaffected skin from normal healthy horses, especially in the acute phase (van der 
Haegen et al., 2001). Skin biopsies from horses with urticaria also revealed more IgE-bearing cells in the 
superficial dermis when compared with skin biopsies obtained from normal horses (Rufenacht et al., 
2005).  
Type I hypersensitivity reactions can be simulated by intradermal injection of anti-IgE antibody 
(Abbas et al., 2012). The anti-IgE functions to cross-link surface IgE, mimicking the effects of an 
allergen. This reaction has been used in humans to evaluate the effects of drugs on IgE-mediated 
reactions (Gronneberg, 1984; Gronneberg and Strandberg, 1985; Gronneberg et al., 1981; Gronneberg 





anti-IgE (Olivry et al., 2001; Pucheu-Haston et al., 2006). Such a model has not been developed in the 
horse. 
The hypothesis of this pilot study was that intradermal injection of 0.08 mg/ml protein G 
affinity-purified anti-canine IgE will cause macroscopic and microscopic reactions similar to those seen 
in horses with allergic skin disease. 
2.2  Materials and Methods 
Four horses (3 geldings, 1 mare) aged 3 to 8 years were used for this study. These horses were 
chosen based upon lack of evidence of current or prior cutaneous or systemic disease (including allergic 
skin disease). All horses were vaccinated for Eastern Equine Encephalitis, Western Equine Encephalitis, 
West Nile Virus Encephalitis, Tetanus, and Influenza, and dewormed with a product containing 
ivermectin or moxidectin (200 μg/kg body weight, orally, twice yearly) as part of routine herd care. No 
medications were given for 14 days prior to the study. Physical examinations were performed on Study 
Day 0. All experimental protocols were approved by the Louisiana State University Institutional Animal 
Care and Use Committee (Protocol #11-072)  
All horses were shaved on the lateral cervical area on Study Day 0 in preparation for injections 
in this location. Horses were sedated with intravenous xylazinea (0.4 mg/kg). All horses were injected 
intradermally (0.1 ml each injection) at one site with phosphate-buffered saline (PBS), at four sites with 
protein G affinity-purified anti-IgEb (Hammerberg et al., 2001) diluted to 0.08 mg/ml in PBS, and at four 
sites with IgGc diluted to 0.1 mg/ml in PBS. Anti-canine IgE was used as anti-equine IgE was not 
available.  Furthermore, preliminary work (data not shown) had demonstrated the ability of anti-canine 
IgE to induce the development of gross and microscopic immediate and late phase reactions in the skin 





Rabbit antisera specific for canine IgE was generated by injection of canine monoclonal IgEd 
produced by a canine x mouse heterohybridoma (Gebhard et al., 1995). Antisera were adsorbed with 
canine IgG linked to beads to remove antibodies cross-reactive with IgG.  
 Anti-IgE and IgG injected skin sites were examined at 20 minutes, and at 6, 24, and 48 hours 
after injection for the development of cutaneous swelling, erythema or induration. The PBS injected 
sites were measured at 20 minutes. The diameter of the cutaneous reactions (wheals) was measured in 
two perpendicular directions and the reaction surface areas were calculated.  Dermal thickness of the 
injected skin was also measured with calipers. 
Horses were sedated with xylazine prior to all skin biopsy acquisitions.  All biopsy areas were 
injected subcutaneously with 0.5 ml of 2% lidocaine hydrochloridee. One 8-mm punch biopsy of normal, 
non-injected skin on the lateral neck was collected at the time of injection. Samples were collected at 
anti-IgE and IgG injection sites at 20 minutes, and 6, 24, and 48 hours after injection.  Each sample was 
bisected immediately after collection. One half was placed in 10% neutral buffered formalin for routine 
processing in paraffin. Fixation time was variable, but was a minimum of 72 hours after sample 
acquisition. The other half was placed in Optimal Cutting Temperature mediumf, frozen in isopentane 
cooled in liquid nitrogen and stored at -80° until cryosectioning. 
Five-micrometer tissue sections were cut from paraffin blocks and stained with hematoxylin and 
eosin for examination, cell enumeration, and pattern analysis. Eosinophils were better visualized using 
Luna’s stain(Luna et al., 1968) for eosinophils . A low-pH (2.5) toluidine blue (T-blue) stain was used to 
facilitate evaluation of dermal mast cells. 
A three-step labeled streptavidin method(Affolter and Moore, 2002) was modified and used to 
characterize the mononuclear cell infiltrate. Briefly, 6-μm cryosections were air dried, then immersed in 





then blocked with 1% fetal calf serum. The blocking sera was drained and mouse-origin monoclonal 
antibodies specific for equine CD4 or CD8 beta chainh were diluted 1:70 in PBS and applied to the 
slides. After rinsing, endogenous peroxide activity was quenched by immersion in 3% hydrogen 
peroxide in PBS. Biotinylated horse-origin anti-mouse IgGi was applied diluted 1:400 in PBS, followed 
by horseradish peroxidase-conjugated streptavidinj diluted 1:400 in PBS. Samples were rinsed with 
0.5% PBST between steps. Amino-9-ethyl carbazolek was applied as a chromogen, followed by 
hematoxylin counterstainl. 
For all cell types, the total number of cells/mm2 in the dermis was obtained by counting sixteen 
0.25 mm x 0.25 mm fields of dermis (excluding epithelial cells and adnexa).  For the H&E, Luna, and T-
blue slides, the sixteen fields were split evenly between four depths of dermis: superficial dermal, 
superficial follicular, deep follicular, and deep follicular to adnexal (Figure 2.1). Total numbers of 
nucleated cells, total granulocytes, and total mononuclear cells were counted using H&E stained slides. 
Eosinophils were counted using the Luna stained slides. A total neutrophil count was obtained by 
determining the difference between the number of eosinophils/mm2 and the number of total 
granulocytes/mm2. The T-Blue stained slides were evaluated for total numbers of intact mast cells as 
well as degranulated mast cells. CD3+, CD4+, and CD8+ dermal cells were counted on sixteen 0.25 mm x 
0.25 mm fields beginning in the superficial dermis (excluding endothelial cells and adnexa) and 
extending deeper as needed. 
Data analysis was performed with statistical softwares. A repeated measures analysis of variance 
with a factorial arrangement of treatments was conducted.  Fixed effects in the model included depth 
(when applicable), time, treatment, and their interactions.  Animal was included as a random 









Figure 2.1: Dermal depths used to evaluate inflammatory cell location in horses. Bar = 200 µm. 
2.3  Results 
Macroscopic Reactions: Overall, anti-IgE injection resulted in significantly larger wheal surface areas 
compared to IgG injection, but there was not a significant Treatment x Time interaction (Figure 2.2A). 
The anti-IgE injection sites were significantly thicker than IgG injected skin at 20 minutes and 6 hours 
(Figure 2.2B).  Dermal thickness in anti-IgE injected skin was greatest 20 minutes after injection and 






Immediate-Phase Reactions: Anti-IgE injected skin had significantly more total mast cells (Figure 2.3A) 
and degranulated mast cells (Figure 2.3B) noted than IgG injected skin, but a significant Treatment x 
Time interaction was not observed.  
 
 
Figure 2.2: Mean ± SE surface area (A) and skin thickness (B) after intradermal injection of anti-IgE at 
4 locations (black bars), rabbit IgG at 4 locations (light gray bars), and PBS solution at 1 location (white 
bars) in 4 clinically normal horses. PBS injected skin samples were measured only at 20 minutes. 
*Within a time period, value differs significantly (P < 0.001) from the value for the IgG injection. † 
Value differs significantly (P < 0.05) from the value for the PBS solution injection at 20 minutes. 
‡Within a treatment, value differs significantly (P < 0.05) from the value at the preceding time point. 
 
Figure 2.3: Mean ± SE number of mast cells (A) and degranulated mast cells (B) in skin samples 
obtained after intradermal injection of anti-IgE (black bars) and rabbit IgG (gray bars) or in noninjected 
skin (white bars) of 4 clinically normal horses. Noninjected skin samples were collected only before 
injection (time 0). The scale for the y-axis differs between panels. Notice that intradermal injection of 






Late-Phase Reactions: The total number of inflammatory cells was not significantly different between 
treatment groups (Figure 2.4A). There were significantly more eosinophils in anti-IgE injected skin 
compared to IgG injected skin, but a significant Treatment x Time interaction was not seen (Figure 
2.4B). There are significantly more eosinophils in the deep follicular and deep follicular to adnexal 
depths for anti-IgE injected skin compared to IgG injected skin. The neutrophil count was not 
significantly different between treatment groups (Figure 2.4C). 
Lymphocyte Profile: There were significantly more CD4+ cells at 24 and 48 hours for IgG injected skin 
when compared to anti-IgE. There was also a significant increase in CD4+ cells from 6 to 24 hours for 
IgG injected samples (Figure 2.5A). There was no significant difference between treatment groups for 
CD8+ cell counts (Figure 2.5B). 
2.4  Discussion 
This study found that intradermal injection of anti-canine IgE (0.8 mg/ml) in normal horses 
failed to produce significant reactions, both macro- and microscopically. This lack of significance may 
have been due to both the concentration of anti-canine IgE used, as well as the low sample size (n=4).  
With a larger number of test subjects, more significant differences may have been seen between 
treatment groups. There was not a significant Treatment x Time effect for wheal surface area (Figure 
2.2A), which would be expected if adequate amounts of anti-IgE were used. Additionally, the only time 
that there was a significant injection site thickness difference between treatment groups was at 20 
minutes. (Figure 2.2B)  In a similar study in dogs, wheals were significantly larger for anti-IgE injection 
sites compared to IgG at 20 minutes and 6 hours (Pucheu-Haston et al., 2006). In another study in dogs, 
significant wheal persistence was observed through 24 hours following anti-IgE injection (Olivry et al., 
2001). At the concentration used in the present study and with the current sample size, anti-IgE did not 






Figure 2.4: Mean ± SE number of inflammatory cells (A), number of eosinophils (B), eosinophil depth 
(C), and number of neutrophils (D) in skin samples obtained after intradermal injection of anti-IgE and 
rabbit IgG or in noninjected skin of 4 clinically normal horses. The scale on the y-axis differs among 
panels. Notice that intradermal injection of anti-IgE causes a late-phase cellular response. *Value differs 
significantly (P < 0.05) from the value for the IgG injection within a dermis depth (panel C). 
 
Figure 2.5:  Mean ± SE number of CD3+ (A), CD4+ (B), and CD8+ (C) cells in skin samples obtained 
after intradermal injection of anti-IgE and rabbit IgG or in noninjected skin of 4 clinically normal 
horses. The scale on the y-axis differs among panels. Notice that intradermal injection of anti-IgE causes 
a late-phase cellular response characterized by the recruitment of CD3+ cells and CD8+ cells. *Value 
differs significantly (P < 0.05) from the value for the IgG injection within a time point. †Value differs 
significantly (P < 0.05) from the value for noninjected skin. ‡Within a treatment, value differs 





Anti-IgE intradermal injection resulted in significantly more mast cells and degranulated mast 
cells than IgG injection skin, but a treatment x time interaction was not noted (Figure 2.3). It is possible 
that an increased concentration of anti-IgE would make the results significant, but this did not prove true 
for the concentration of anti-IgE used in the study presented in Chapter 3. Further possible causes for the 
lack of mast cell significance are addressed in that chapter.  
In the present study, the total number of inflammatory cells was not significantly different 
between treatment groups (Figure 2.4A). This lack of response may be due to the decreased 
concentration of anti-IgE used in the study, as significant differences between the two groups were noted 
when a higher concentration of anti-IgE was used. (Chapter 3). While there were overall significantly 
more eosinophils in anti-IgE injected skin compared to IgG, a significant Type x Time interaction was 
not noted (Figure 2.4B). This is in contract to the subsequent high-dose study (Chapter 3), where 
eosinophils were significantly increased following anti-IgE injection at 6, 24, and 48 hours. Again, the 
lack of significance shown in this study is assumed to be due to the decreased concentration of anti-IgE, 
as well as the decreased sample size of the other study (4 horses vs. 6 horses).  
There were significantly more CD4+ cells in IgG injected skin compared to anti-IgE samples at 
24 and 48 hours (Figure 2.5A). As discussed in Chapter 3, the results may also have been affected by the 
difficulty encountered in performing and evaluating IHC on frozen tissues. This unexpected different in 
CD4+ cells was no longer apparent when a higher concentration of anti-IgE was used (Chapter 3). There 
was not a significant difference between treatment groups for CD8+ cells (Figure 2.5 B). Similar results 
were seen with higher concentrations of anti-IgE (Chapter 2). This cell type has not been frequently 
evaluated in horses with allergic skin disease, so expected results are unknown. 
Intradermal injection of anti-IgE has been used in human and dogs to create a model of allergic 





inflammatory reactions (Gronneberg, 1984; Gronneberg and Raud, 1996; Gronneberg and Strandberg, 
1985; Gronneberg et al., 1981; Gronneberg and Zetterstrom, 1985a, b, 1990b; Pucheu-Haston et al., 
2006). At the concentrations used in the present study, anti-IgE did not produce expected results, 
suggesting that an anti-IgE concentration of 0.08 mg/ml would not be suitable for use in modeling 
equine allergic skin disease.   
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CHAPTER 3   CHARACTERIZATION OF IgE-MEDIATED (HIGHER 
CONCENTRATION) CUTANEOUS IMMEDIATE AND LATE-PHASE REACTIONS 
IN NON-ALLERGIC HORSES 
3.1  Introduction 
Anti-IgE antibodies have been used in the past to model allergic skin disease in dogs and humans 
(Gronneberg and Raud, 1996; Gronneberg and Strandberg, 1985; Gronneberg et al., 1981; Gronneberg 
and Zetterstrom, 1985a, b, 1990a). However, no work is available regarding the use of anti-canine IgE in 
horses and the ideal concentration of anti-IgE needed to induce significant immediate- and late-phase 
reactions is unknown.  
The purpose of this study was to expand upon our prior work in which we found that intradermal 
injection of 0.08 mg/ml of anti-IgE produced a weak gross and microscopic inflammatory response with 
some similarities to the inflammation seen in spontaneous allergic disease.  The hypothesis of the 
present study was that normal horses would have macroscopic and microscopic reactions similar to 
horses with allergic skin disease following intradermal injection of anti-IgE at a concentration 0.1 
mg/ml. Additionally, these reactions would be comparable to those seen in dogs following similar 
injection. 
3.2  Materials and Methods 
Six horses (3 geldings, 3 mares) aged 4 to 8 years were used for this study. These horses were chosen 
based upon lack of evidence of current or prior cutaneous or systemic disease (including allergic skin 
disease). All horses were vaccinated for Eastern Equine Encephalitis, Western Equine Encephalitis, 
West Nile Virus Encephalitis, Tetanus, and Influenza, and dewormed with a product containing 
ivermectin or moxidectin (200 μg/kg body weight, orally, twice yearly) as part of routine herd care. No 





Day 0. All experimental protocols were approved by the Louisiana State University Institutional Animal 
Care and Use Committee (Protocol #11-072)  
All horses were shaved on the lateral cervical area on Study Day 0 in preparation for injections 
in this location. Horses were sedated with intravenous xylazinea (0.4 mg/kg). All horses were injected 
intradermally (0.1 ml each injection) at one site with phosphate-buffered saline (PBS), at four sites with 
protein G affinity-purified anti-IgEb (Hammerberg et al., 2001) diluted to 0.1 mg/ml in PBS, and at four 
sites with IgGc diluted to 0.1 mg/ml in PBS. Anti-canine IgE was used as anti-equine IgE was not 
available.  Furthermore, preliminary work (data not shown) had demonstrated the ability of anti-canine 
IgE to induce the development of gross and microscopic immediate and late phase reactions in the skin 
of normal horses. 
Rabbit antisera specific for canine IgE was generated by injection of canine monoclonal IgEd 
produced by a canine x mouse heterohybridoma (Gebhard et al., 1995). Antisera were adsorbed with 
canine IgG linked to beads to remove antibodies cross-reactive with IgG.  
 Anti-IgE and IgG injected skin sites were examined at 20 minutes, and at 6, 24, and 48 hours 
after injection for the development of cutaneous swelling, erythema or induration. The PBS injected 
sites were measured at 20 minutes. The diameter of the cutaneous reactions (wheals) was measured in 
two perpendicular directions and the reaction surface areas were calculated.  Dermal thickness of the 
injected skin was also measured with calipers. 
Horses were sedated with xylazine prior to all skin biopsy acquisitions.  All biopsy areas were 
injected subcutaneously with 0.5 ml of 2% lidocaine hydrochloridee. One 8-mm punch biopsy of normal, 
non-injected skin on the lateral neck was collected at the time of injection. Samples were collected at 
anti-IgE and IgG injection sites at 20 minutes, and 6, 24, and 48 hours after injection.  Each sample was 





processing in paraffin. Fixation time was variable, but was a minimum of 72 hours after sample 
acquisition. The other half was placed in Optimal Cutting Temperature mediumf, frozen in isopentane 
cooled in liquid nitrogen and stored at -80° until cryosectioning. 
Five-micrometer tissue sections were cut from paraffin blocks and stained with hematoxylin and 
eosin for examination, cell enumeration, and pattern analysis. Eosinophils were better visualized using 
Luna’s stain(Luna et al., 1968) for eosinophils . A low-pH (2.5) toluidine blue (T-blue) stain was used to 
facilitate evaluation of dermal mast cells. 
A three-step labeled streptavidin method (Affolter and Moore, 2002) was modified and used to 
characterize the mononuclear cell infiltrate. Briefly, 6-μm cryosections were air dried, then immersed in 
acetone for fixation. The samples were rinsed with PBS containing 0.5% Tween 20 (0.5% PBST)g and 
then blocked with 1% fetal calf serum. The blocking sera was drained and mouse-origin monoclonal 
antibodies specific for equine CD4 or CD8 beta chainh were diluted 1:70 in PBS and applied to the 
slides. After rinsing, endogenous peroxide activity was quenched by immersion in 3% hydrogen 
peroxide in PBS. Biotinylated horse-origin anti-mouse IgGi was applied diluted 1:400 in PBS, followed 
by horseradish peroxidase-conjugated streptavidinj diluted 1:400 in PBS. Samples were rinsed with 
0.5% PBST between steps. Amino-9-ethyl carbazolek was applied as a chromogen, followed by 
hematoxylin counterstainl. 
For CD3 immunohistochemistry, slides were deparaffinized in three changes of xylene for five 
minutes each. The samples were then rehydrated in three changes of 100% alcohol and one change of 
95% alcohol for five minutes each before being rinsed three times in deionized water. Antigen retrieval 
was performed with 10mM citrate buffer (pH 6.0) for 10 minutes at 125-127° C (Biocare Decloaker) 
and then slides were cooled for twenty minutes before being rinsed three times each with deionized 





AutoStainer LINK 48. Endogenous peroxide activity was blocked with 3% hydrogen peroxide for three 
minutes before a buffer rinse. Nonspecific antibody binding was blocked by incubation with normal goat 
serum for 30 minutesm followed by incubation with the primary antibody of 1:400 rabbit anti-human 
CD3n for 30 minutes followed by a buffer rinse. The sample was then incubated with secondary 
antibody of biotinylated anti-rabbit secondary antibodyo for 30 minutes followed by a buffer rinse. The 
tissue samples were then exposed to the detection reagent avidin/biotinylated enzyme complexp for 30 
minutes before a buffer rinse and application of NovaRedq followed by a buffer rinse and then deionized 
water. The samples were counterstained for five minutes with Mayers hematoxylin (Lillie’s 
modification)r rinsed again with buffer and then deionized water, and removed from the stainer. Slides 
were dried in an oven at 60° C for thirty minutes before being removed and cooled for five to ten 
minutes. Slides were rinsed in three changes of xylene for three minutes each before being coverslipped.  
For all cell types, the total number of cells/mm2 in the dermis was obtained by counting sixteen 
0.25 mm x 0.25 mm fields of dermis (excluding epithelial cells and adnexa).  For the H&E, Luna, and T-
blue slides, the sixteen fields were split evenly between four depths of dermis: superficial dermal (A), 
superficial follicular (B), deep follicular (C), and deep follicular to adnexal (D) (Figure 2.1). Total 
numbers of nucleated cells, total granulocytes, and total mononuclear cells were counted using H&E 
stained slides. Eosinophils were counted using the Luna stained slides. A total neutrophil count was 
obtained by determining the difference between the number of eosinophils/mm2 and the number of total 
granulocytes/mm2. The T-Blue stained slides were evaluated for total numbers of intact mast cells as 
well as degranulated mast cells. CD3+, CD4+, and CD8+ dermal cells were counted on sixteen 0.25 mm x 
0.25 mm fields beginning in the superficial dermis (excluding endothelial cells and adnexa) and 





Data analysis was performed with statistical softwares. A repeated measures analysis of variance 
with a factorial arrangement of treatments was conducted.  Fixed effects in the model included depth 
(when applicable), time, treatment, and their interactions.  Animal was included as a random 
effect.  When overall significance was detected (p≤0.05), post hoc comparisons were made with 
pairwise t tests of least-squares means. This was done for all dermal cell counts as well as injection site 
measurements. 
3.3  Results  
Macroscopic Reactions: Intradermal injection of anti-IgE produced erythematous and indurated local 
urticarial reactions within 20 minutes in all horses. The surface areas of these reactions were 
significantly larger than normal rabbit IgG injected sites at 20 minutes, 6 and 24 hours after injection 
(Figure 3.1A).  The areas of dermal induration in anti-IgE injected skin significantly increased from 20 
minutes to 6 hours and from 6 to 24 hours. Anti-IgE injection sites were significantly larger than PBS 
injected skin at 20 minutes, except at 48 hours. IgG injection sites, when measurable, were never 
significantly different from PBS injected skin at 20 minutes. There were no measurable wheals or 
induration for IgG injected skin at 24 or 48 hours or for anti-IgE injected skin at 48 hours.  
The anti-IgE injection sites were significantly thicker than IgG injected skin at 20 minutes, 6 
hours, and 24 hours (Figure 3.1B). Dermal thickness in anti-IgE injected skin was greatest 20 minutes 
after injection and decreased significantly compared to the previous values at all time points (e.g., from 
20 minutes to 6 hours, from 6 to 24 hours and from 24 to 48 hours). Anti-IgE injection site thickness at 
20 minutes and 6 hours was significantly greater than PBS thickness, but was significantly less than PBS 








Figure 3.1: Intradermal injection of anti-canine IgE (but not normal rabbit IgG) induces the formation of 
a measurable wheal. (A) Injection site surface area and (B) injection site thickness. * Value differs 
significantly (P<0.001) between treatment groups. † Significant difference (P<0.05) from previous 
measured value for the same treatment group. 
Immediate-Phase Reactions: There was no significant difference in the total number of mast cells seen 
between treatment groups (Figure 3.2A). The mean number of degranulated mast cells were 
significantly (P<0.0001) higher in anti-IgE treated skin when compared to IgG injected skin, but a 
treatment x time interaction was not found (Figure 3.2B).  
Late-Phase Reactions: The total number of inflammatory cells increased up to 24 hours after anti-IgE 
injection when compared to time 0 (Figure 3.3A) and there were significantly more inflammatory cells 
in anti-IgE injected skin compared to IgG injected skin at 6 and 24 hours. By 48 hours, the total number 
of inflammatory cells decreased in anti-IgE injected skin and were no longer significantly different when 
compared to inflammatory cell counts in non-injected control skin. 
Luna staining revealed a significant increase in the number of eosinophils in anti-IgE injected 
skin from 20 minutes to 6 hours and 6 to 24 hours (Figure 3.3C). Then, eosinophil counts significantly 
decreased from 24 to 48 hours. There were significantly more eosinophils for anti-IgE injected skin 
compared to IgG injected skin at 6 hours (P=0.0015), 24 hours (P<0.0001), and 48 hours (P=0.0013). 





(P=0.0011), 24 hours (P<0.0001), and 48 hours (P=0.0013). Eosinophil counts were not significantly 
different in IgG injected skin when compared to non-injected skin at any time point. 
 
Figure 3.2: Intradermal injection of anti-canine IgE produces mast cell degranulation. (A) Total mast 
cells and (B) degranulated mast cells. 
There was a significant treatment x depth effect for eosinophils. Eosinophil counts were 
significantly higher in the deeper dermis at the superficial follicular (P<0.0014), deep follicular  
(P<0.0001), and deep follicular to adnexal (P<0.0001) depths, for anti-IgE samples when compared to 
IgG tissue (Figure 3.3C). Eosinophil counts did not differ between treatment groups at the depth of the 
superficial dermis.    
Neutrophils were significantly increased in anti-IgE injected skin from 20 minutes to 6 hours.  
Neutrophil counts decreased significantly from 6 to 24 hours and 24 to 48 hours (Figure 3.3D). For anti-
IgE injected skin, there were significantly more neutrophils at 6 hours compared to IgG injected skin. 
Significantly more neutrophils were seen in anti-IgE injected skin compared to non-injected skin at 6 
and 24 hours. Neutrophil counts in IgG injected skin did not differ from non-injected skin at any time 
point.  
Lymphocyte Profile: There was no significant difference between CD3+, CD4+, or CD8+ (Fig 3.4) cell 






Figure 3.3: Intradermal injection of anti-canine IgE produces a late-phase cellular response. (A) Total 
inflammatory cells, (B) eosinophils, (C) eosinophil depth, and (D) neutrophils. * Value differs 
significantly (P<0.05) between treatment groups. † Significant difference (P<0.05) from previous 
measured value for the same treatment group. ‡ Significant difference (P<0.05) from noninjected skin. 
3.4  Discussion and Conclusions   
 The present study confirmed that intradermal injection of protein G affinity-purified rabbit-
origin polyclonal IgG specific for canine IgE produced many macro- and microscopic changes in normal 
horses similar to those seen in humans and dogs in similar studies. Anti-equine IgE was not available for 
use in the present study, but would be expected to produce similar results. The reported protein sequence 
of canine IgE is approximately 65-67% identical with that of equine IgE (as determined by BLASTt 
(Altschul et al., 1997; Altschul et al., 2005)), which would suggest sufficient similarity to permit cross-
species use.  This assumption is supported by the fact that some commercially available anti-canine IgE 





(B. Hammerberg, unpublished study) has demonstrated that both rabbit polyclonal anti-canine IgE and 
mouse monoclonal anti-IgE were able to induce immediate wheal-and-flare responses in the skin of 
normal horses following intradermal injection.  
 
Figure 3.4: Intradermal injection of anti-canine IgE produced a late-phase cellular response 
characterized by the recruitment of CD3 and CD8 positive cells. (A) CD3, (B) CD4, (C) CD8. 
Intradermal injection of cross-linking anti-IgE induced an immediate wheal response at 20 
minutes, which continued to increase in surface area through 24 hours (Figure 3.1A). In a similar study 
in dogs, a significantly larger wheal was noted for anti-IgE injection when compared to IgG at 20 
minutes and 6 hours, but was not seen at 24 or 48 hours (Pucheu-Haston et al., 2006). In another study in 
dogs, urticaria was observed through 24 hours, though lesions decreased in size up to that point (Olivry 
et al., 2001). Thus, it appears that horses may have a more prolonged macroscopic late-phase reaction 





Intradermal injection of PBS and IgG also produced measurable distention of the skin, but these 
areas were significantly smaller and less indurated than anti-IgE wheals (Figure 3.1B). Additionally, 
injection site surface area associated with IgG injection was absent by 24 hours. Injection of any 
substance intradermally will cause a transient distention of the superficial dermis, but this distention will 
become absent with time as the substance is reabsorbed. This likely accounts for the initial injection site 
measurements seen with IgG and PBS.  
The use of stereological methods of counting cells (rather than manual cell counting, as was 
performed here) was considered in the design of this study. However, these programs were not used for 
several reasons. The first reason is the complex structure of the superficial and middle dermis.  In these 
areas, there are numerous non-dermal structures, including the papillary epidermis, hair follicles, 
sebaceous glands, muscles, blood vessels, and nerves. In order to count a consistent area of dermis, these 
structures need to be excluded from the area to be evaluated, which is easiest for a human to do. 
Additionally, these other structures, and their associated cell types (keratinocytes, sebocytes, endothelial 
cells) can make identifying specific cell types of interest (mononuclear cells, granulocytes) very 
difficult. For these reasons, we chose to employ a manual cell count method in this study. 
Although anti-IgE intradermal injection tissue had significantly more degranulated mast cells 
than non-injected and IgG injected skin, a treatment x time interaction was not apparent. One possible 
reason for a lack of statistical significance with regards to degranulated mast cells is the difficulty in 
visualizing them once they have degranulated and lose their staining capabilities, leading to variability 
in cell counts. This degranulation phenomenon has been noted previously in humans (Claman et al., 
1986) and has been postulated to occur in horses (Rufenacht et al., 2005). Van der Haegen et al (van der 
Haegen et al., 2001) examined mast cells in skin of horses with IBH and evaluated their numbers with 





was also evaluated. The results of that study revealed that toluidine-blue staining was significantly 
decreased in samples that were fixed for periods longer than 24 hours. Additionally, more tryptase+ 
mast cells were seen in samples fixed for less than 24 hours when compared to samples fixed for longer 
periods of time (van der Haegen et al., 2001). Thus, it might be beneficial, in future studies using the 
model developed in the present study, to either shorten fixation times for toluidine-blue stained samples, 
or to additionally include tryptase staining when evaluating mast cells in equine allergic skin disease. 
In the present study, the total number of inflammatory cells was increased at 6 and 24 hours after 
injection with anti-IgE compared to IgG injection (Figure 3.3A). This timing was consistent with a late-
phase reaction with influx of inflammatory cells. Eosinophils, in particular, were increased at 6, 24, and 
48 hours for anti-IgE injected skin when compared to IgG and non-injected skin. Various chemokines 
(e.g. CCL11, CCL24, and CCL26) have been shown to recruit eosinophils and are produced by different 
cell types (e.g. epithelial cells) (Abbas et al., 2012). In the current study, eosinophil recruitment was 
likely due to chemotactic factors produced by degranulating mast cells, as the horses in this study were 
unlikely to have a pre-existing hypersensitivity to the anti-IgE antibody and thus would not be expected 
to have a local population of sensitized TH2 lymphocytes. Eosinophils are also recruited and activated by 
TH2 cell cytokines in late-phase reactions (Abbas et al., 2012). Future studies could evaluate tissue 
sections for increased levels of these chemokines or of IL-5, a potent eosinophil activating cytokine that 
is produced by mast cells and TH2 cells. 
Historically, eosinophilic dermatitis has been consistently seen with acute allergic skin disease in 
the horse, however the depth of eosinophilic infiltration was either not described or comparisons of the 
relative numbers of eosinophils at different depths were not made (Fadok and Greiner, 1990; Foster et 
al., 1995; McKelvie et al., 1999; Rufenacht et al., 2005; Scott, 2010; van der Haegen et al., 2001). In the 





Previous studies evaluating anti-IgE intradermal injection in dogs have only described cellular counts in 
the most superficial dermis (Pucheu-Haston et al., 2006).  The results of the study reported here 
demonstrated that there was no significant difference in eosinophil numbers between anti-IgE and IgG 
injected skin in the superficial dermis (Figure 3.3C). However, eosinophil numbers were increased at the 
depth of the follicle and deeper dermis in anti-IgE injected skin. Had this study not evaluated depth as a 
factor, a significant part of the late-phase reaction (eosinophil recruitment) might have been missed. The 
reason for the increased eosinophil recruitment to the deeper dermis is not known. Further studies would 
be useful to evaluate the depth of eosinophils in naturally occurring equine allergic skin disease.  
Quantitation of CD3+, CD4+, and CD8+ cells over time in this study did not demonstrate 
significant differences between anti-IgE and IgG injected skin. The CD3 stained slides were assessed on 
formalin fixed, paraffin tissue and should be evaluated separately from the CD4 and CD8 cells counts, 
which were obtained from frozen tissue. This may account for the decreased number of CD3+ cells seen 
compared to the sum of CD4+ and CD8+ counts (as all of these cells should also be CD3+). The anti-IgE 
injected skin showed increased numbers of CD3+ cells, when compared to IgG injected skin, from 20 
minutes to 24 hours with a subsequent decrease in cell counts at 48 hours, but these trends were not 
significant (Figure 3.4A). This trend was similar to results from a previous study in dogs in which CD3+ 
cells increased by 6 hours and peaked 24 hours after anti-IgE injection(Pucheu-Haston et al., 2006). 
Another study evaluating late-phase reactions after intradermal injection of anti-IgE in dogs found that 
CD3+ dermal cell counts increased from 6 to 48 hours after injection (Olivry et al., 2001). McKelvie et 
al. evaluated the skin lymphocyte populations in horses with IBH (McKelvie et al., 1999) and found that 
there were an increased number of CD3+ lymphocytes (many of which were also CD4+) in the skin of 
horses with IBH following injection with Culicoides antigen.  These late-phase changes were not seen in 
the present study.  However, McKelvie et al. only evaluated horses with signs of IBH, which horses in 





with allergic horses that were injected intradermally with specific antigen, the results would be more 
similar to those seen by McKelvie et al. Additionally, it must be kept in mind that the McKelvie study 
evaluated the response to whole-body Culicoides extract, which may have included proteases and other 
irritants. This extract failed to produce a gross whealing response in non-allergic ponies in a prior study 
and the histology of the Culicoides injection sites was not evaluated in these animals (Foster et al., 
1998).  For this reason, it is difficult to ascertain whether these lymphocyte responses truly represent an 
antigen-specific phenomenon. 
The CD4+ cell counts in this study were not consistent with findings in previous studies 
(Heimann et al., 2011; McKelvie et al., 1999). One study evaluating Icelandic horses with insect bite 
hypersensitivity found an increase in CD4+ cells in skin samples of affected horses (Heimann et al., 
2011). Although the cause of the lack of increase of CD4+ cells in this study is not known, it may be 
partially attributed to the difficulty in performing and evaluating IHC on frozen tissues. These samples, 
in general, did not maintain the architecture of the skin well and were more difficult to stain than 
paraffin tissue. In addition, the use of anti-canine IgE (rather than anti-equine IgE) may have led to the 
difference in CD4+ populations, possibly due to a lower affinity and thus a less robust inflammatory 
response.  However, this possibility seems somewhat unlikely due to the similar reaction in other cell 
populations. 
CD8+ cells have been evaluated less often than CD3+ and CD4+ in horse skin. In the present 
study, CD8+ cells increased in anti-IgE injected skin from 20 minutes to 24 hours and then decreased at 
48 hours (similar to the CD3+ cell counts) (Figure 3.4C). However, the increase was not significantly 
different from IgG injected skin. One study evaluating CD8+ cells found significantly more dermal 
CD4+, but not more CD8+, cells in horses with IBH lesional skin compared to healthy horses (Heimann 





The horses in this study developed significant gross and histologic reactions following 
intradermal injection of anti-IgE. In order to do so, IgE must have been present to some degree at the 
sites of injection prior to the study. Previous studies have shown that horses that do not have clinical 
allergic skin disease can still be sensitized to allergens and show positive reactions to intradermal 
injection (Lorch et al., 2001a; Lorch et al., 2001b; Wagner et al., 2009). Anti-IgE, unlike specific 
allergens, crosslinks all IgE, regardless of allergen specificity. Previous studies in horses have 
demonstrated that IgE on mast cells can be non-specifically cross-linked by anti-IgE, even in non-
allergic horses (Wagner et al., 2006; Wagner et al., 2003; Wilson et al., 2006). The ability of the horses 
in this study to develop a response to anti-IgE therefore does not necessarily reflect allergy or 
parasitism.  
As previously discussed, intradermal injection of anti-IgE has been used in human and dogs to 
create a model of allergic skin disease and to evaluate the effects of different pharmaceutical agents on 
immediate and late-phase inflammatory reactions (Gronneberg, 1984; Gronneberg and Raud, 1996; 
Gronneberg and Strandberg, 1985; Gronneberg et al., 1981; Gronneberg and Zetterstrom, 1985a, b, 
1990b; Pucheu-Haston et al., 2006). The study reported here confirms that injection of anti-IgE produces 
a dermal inflammatory response with many similarities to that seen in spontaneous allergic skin disease 
in horses. These similarities were particularly marked for eosinophils and neutrophils, although the 
lymphocyte response generated in this study was lesser in magnitude that what would be expected. In 
the future, controlled studies using this model could be performed to evaluate the effectiveness of 
different treatment modalities and their effects on macro- and microscopic reactions for allergic skin 
disease in horses without having to maintain a herd of allergic horses. 
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CHAPTER 4 FINAL DISCUSSION AND CONCLUSIONS 
Intradermal injection of anti-IgE induced macroscopic and microscopic reactions in 
horses that were similar to those seen in naturally occurring allergic disease, but only at a higher 
concentration of 0.1 mg/ml. At a lower concentration (0.08 mg/ml), the difference between anti-
IgE injection and IgG injection was less significant, suggesting that this lower dose was 
suboptimal for modeling dermal IgE-mediated inflammation. Although the results were not 
precisely what was expected when compared to previous studies in other species, this may be 
secondary to species-specific differences. In the future, the model developed in this paper could 
be used to evaluate different medical therapies for equine allergic skin disease secondary to type 
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